Lyme disease investigational drug: FDA accepts IND application

By NewsDesk @infectiousdiseasenews Biopharmaceutical company, Tarsus Pharmaceuticals, recently announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease. With this IND acceptance, Tarsus will initiate a Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) [...]

The post Lyme disease investigational drug: FDA accepts IND application appeared first on Outbreak News Today.